FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
| | | | |

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

On Oct. 10, 2024, Genentech announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib),…

Strengthening the U.S. Biomedical Research Enterprise Entails National Strategic Coordination, Focus on Health Equity
| | | | | | | | | |

Strengthening the U.S. Biomedical Research Enterprise Entails National Strategic Coordination, Focus on Health Equity

On Oct. 1, 2024, the National Academy of Medicine (NAM) announced a study showing that although the U.S….

CIRM awarded $53 million to clinical research in heart failure and cystic fibrosis, supporting 10 translational projects
| | | | | | | |

CIRM awarded $53 million to clinical research in heart failure and cystic fibrosis, supporting 10 translational projects

On May 30, 2024, the California Institute for Regenerative Medicine (CIRM) announced it had awarded $53 million to…